title: Analytic performance evaluation of a new turbidimetric immunoassay for phenytoin on the ADVIA 1650 analyzer: effect of phenytoin metabolite and analogue.
abstract: Phenytoin is an anticonvulsant that requires therapeutic drug monitoring. Recently, Bayer HealthCare, Diagnostics Division released a turbidimetric immunoassay of phenytoin on the ADVIA 1650 analyzer. We evaluated the analytic performance of this assay by comparing values obtained in 52 patients receiving Phenytoin using this new assay with the values obtained by using a widely used fluorescence polarization immunoassay (FPIA). The new turbidimetric immunoassay for phenytoin showed the following imprecision with the low, medium, and high controls: total CV of 5.2% (mean 4.81 microg/mL), 3.7% (mean 16.24 microg/mL), and 4.1% (mean 22.65 microg/mL), respectively. The detection limit of the assay was 0.79 microg/mL, and the assay was linear up to a phenytoin concentration of 46.1 microg/mL. The assay showed excellent dilution recovery and recovery of spiked samples (mean recovery 101.4% and 94.4%, respectively). We observed an excellent correlation between the values obtained by the FPIA (x-axis) assay and the new turbidimetric (y-axis) assay (y=1.06 x-0.61, r=0.98, n=52). We also determined the cross-reactivity of 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH), a major metabolite of phenytoin, and of oxaprozine, an analogue with a similar chemical structure to phenytoin, in both phenytoin assays. Both assays showed almost no cross-reactivity to oxaprozine and only small (5%-8%) cross-reactivity to HPPH. We also found that the turbidimetric assay was free from interference at least up to 1200 mg/dL of hemolysis, 30 mg/dL of free bilirubin, 34.5 mg/dL of conjugated bilirubin, and 750 mg/dL of triglyceride (Intralipid). When a drug-free serum was followed by a serum sample containing 38.5 microg/mL of phenytoin, no sample probe carryover effect was observed. We conclude that the new turbidimetric assay can be used for routine monitoring of phenytoin in clinical laboratories.
authors.affiliation: Bayer HealthCare, Diagnostics Division, Tarrytown, New York 10591, USA. pradip.Datta.b@bayer.com
authors.forename: Pradip
authors.initials: P
authors.lastname: Datta
authors.forename: Deven
authors.initials: D
authors.lastname: Scurlock
authors.forename: Amitava
authors.initials: A
authors.lastname: Dasgupta
mesh_terms: D001663:Bilirubin / Q000097:blood; D003429:Cross Reactions; D016231:Fluorescence Polarization Immunoassay / Q000295:instrumentation*; D006461:Hemolysis; D006801:Humans; D009391:Nephelometry and Turbidimetry; D000077431:Oxaprozin; D010672:Phenytoin / Q000097:blood*; D011422:Propionates / Q000097:blood
chemical_list: D011422:Propionates; D010672:Phenytoin; D000077431:Oxaprozin; D001663:Bilirubin